Dr. Mrunal serves as Vice President of Research and Development at USP India, where she oversees a comprehensive R&D laboratory comprising the Compendial Development Laboratory, Analytical R&D, and Synthetic Chemistry Laboratory. With responsibility for Scientific Affairs and Strategy functions at USP India, she brings nearly three decades of pharmaceutical industry expertise to her leadership role.
Throughout her distinguished career spanning over 29 years, including 9.5 years with USP India, Dr. Mrunal has established herself as a preeminent figure in pharmaceutical analysis and research. Her expertise encompasses the development, validation, and transfer of stability-indicating analytical methods for drug substances and products. She has made significant contributions to the estimation of potential genotoxic impurities using advanced techniques such as LC-MS/MS and GC-MS/MS.
Dr. Mrunal leads the global Nitrosamine Impurities Workstream, where she has been instrumental in formulating USP's "Focused Nitrosamine Strategy." Her team's primary responsibilities include developing and validating analytical methods for monograph modernization, synthesizing bulk materials of impurities and APIs, and characterizing them to support the development of documentary standards for drug substances, drug products, excipients, and food.
Her exceptional contributions to the field have been recognized with prestigious accolades, including the 'Prof. Dr. R. T. Sane - Outstanding Pharmaceutical Analyst Award' at the 20th IDMA-APA Pharmaceutical Analysts Convention in May 2018, and the award for 'Excellent Contribution in field of Pharmaceutical Research' at the Health & Wellness Conclave in Dehradun in March 2021.
Prior to joining USP India, Dr. Mrunal successfully led Analytical Research and Development departments in various capacities across both Indian and multinational organizations, consistently demonstrating her expertise and commitment to advancing pharmaceutical science